Our Health Library information does not replace the advice of a doctor. Please be advised that this information is made available to assist our patients to learn more about their health. Our providers may not see and/or treat all topics found herein.

Breast Cancer Types

Overview

Breast cancer is the abnormal growth of the cells that line the ducts and lobes of the breast.

When breast cancer has spread outside the ducts or lobes into normal breast tissue, it is said to be invasive. The main types of invasive breast cancer are:

  • Ductal carcinoma. This cancer begins in the ducts of the breast. It's the most common type of breast cancer.
  • Lobular carcinoma. This cancer begins in the lobes of the breast. It's the second most common type.

Some breast cancer is a mixture of both ductal and lobular carcinoma.

There are also some less common types of invasive breast cancer, such as inflammatory breast cancer and male breast cancer.

When abnormal cells in the lining of a duct or lobe of the breast haven't spread, they are said to be noninvasive, or "in situ" (say "in-SY-too"). These include:

  • Ductal carcinoma in situ (DCIS). This is a precancer that may progress to breast cancer. The abnormal cells are only in the ducts of the breast.
  • Lobular carcinoma in situ (LCIS). Because LCIS cells don't spread, it's not considered to be cancer. But having LCIS increases a person's risk of developing breast cancer later in life.

Other factors

Some breast cancer cells have:

  • Hormone receptors for estrogen and progesterone. Some breast cancers need the hormones estrogen or progesterone (or both) to grow. These cancer cells have "receptors" on their surfaces. Receptors are like doorways to let hormones in. These types of cancer are called estrogen-receptor-positive (ER+) and progesterone-receptor-positive (PR+) breast cancer.
  • Large amounts of a protein called HER-2. And some breast cancers also have a large amount of a protein called human epidermal growth factor receptor 2 (HER-2 or HER-2/neu). These breast cancers tend to grow faster and spread more quickly than breast cancers without as much HER-2. So, HER-2 positive (HER-2+) breast cancers are usually treated with a targeted medicine (such as trastuzumab) and chemotherapy.

If the breast cancer cells don't have estrogen receptors, progesterone receptors, or large amounts of HER-2 protein, they are said to be triple-negative. Triple-negative breast cancer is a less common type of breast cancer. It tends to grow faster and spread more quickly and is harder to treat than breast cancers that have hormone receptors. Medicines that target hormone receptors or HER-2 won't help with triple-negative cancer, but chemotherapy can help.

Credits

Current as of: October 25, 2024

Author: Ignite Healthwise, LLC Staff
Clinical Review Board
All Ignite Healthwise, LLC education is reviewed by a team that includes physicians, nurses, advanced practitioners, registered dieticians, and other healthcare professionals.

Current as of: October 25, 2024

Author: Ignite Healthwise, LLC Staff

Clinical Review Board
All Ignite Healthwise, LLC education is reviewed by a team that includes physicians, nurses, advanced practitioners, registered dieticians, and other healthcare professionals.

Dear patient

I am excited to announce that I will be relocating my practice to Houston Methodist DeBakey Cardiology Associates. Starting November 4, 2024, my new address will be:

5115 Fannin, Suite 801
Houston, TX 77004

Please note that my phone number and fax number will also change to the following:
24-Hour Telephone: 713-441-1100
Fax: 713-790-2643
Clinical Support Telephone (M-F, 8-5): 713-441-3515

I am excited about caring for you in my new office and hope you will make the transition with me. I will also continue to refill your medications as I have in the past. To assist, please provide your pharmacy with my new contact information.

Please consider checking your prescription refills to verify that you have enough medication on hand to last you until your next visit. Please note that your medical records will remain at my former office until you authorize their transfer. If you choose for me to continue providing your medical care, please complete and sign the enclosed “Authorization for Release of Medical Records” form and fax it to 713-790-2643. Once we receive your authorization, we will be happy to process the request for you.

Thank you for entrusting me with your medical care. My new team and I are dedicated to making this transition as seamless as possible. For help scheduling an appointment and transitioning your care, please call my new office number above.

I look forward to continuing your care at my new location.

Sincerely,
Gopi A. Shah, MD

Dear patient

Dr. Albert Raizner, Dr. Michael Raizner, and Dr. Mohamed El-Beheary are excited to announce that our practice, Interventional Cardiology Associates, will merge with Houston Cardiovascular Associates on November 1, 2024.

Our new offices are similarly located in Houston, near the Texas Medical Center and in Sugar Land. Our in-hospital care will continue at Houston Methodist Hospital in the Texas Medical Center and Houston Methodist Sugar Land Hospital. Importantly, our new offices expand our services with state-of-the-art equipment and amenities. Our core values will always be, as they began over 40 years ago when Dr. Albert Raizner founded ICA:

Integrity – Compassion – Accountability

Our new address and contact information are:

Your medical records are confidential and remain available at our new locations. We consider it a privilege to serve as your cardiologists and look forward to your continuing with us. However, should you desire to transfer to another physician, you may request a copy of your records by contacting us at our new addresses and phone numbers listed above.

We thank you for your trust and loyalty. As always, we will continue to be here to take care of you. Please do not hesitate to contact us if you have any questions or concerns.

Sincerely,

Dr. Albert Raizner,
Dr. Michael Raizner,
Dr. Mohamed El-Beheary